These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
62 related articles for article (PubMed ID: 18374176)
1. Detection of compounds that rescue Rab1-synuclein toxicity. Fleming J; Outeiro TF; Slack M; Lindquist SL; Bulawa CE Methods Enzymol; 2008; 439():339-51. PubMed ID: 18374176 [TBL] [Abstract][Full Text] [Related]
2. Compounds from an unbiased chemical screen reverse both ER-to-Golgi trafficking defects and mitochondrial dysfunction in Parkinson's disease models. Su LJ; Auluck PK; Outeiro TF; Yeger-Lotem E; Kritzer JA; Tardiff DF; Strathearn KE; Liu F; Cao S; Hamamichi S; Hill KJ; Caldwell KA; Bell GW; Fraenkel E; Cooper AA; Caldwell GA; McCaffery JM; Rochet JC; Lindquist S Dis Model Mech; 2010; 3(3-4):194-208. PubMed ID: 20038714 [TBL] [Abstract][Full Text] [Related]
3. Membrane binding, internalization, and sorting of alpha-synuclein in the cell. Masaracchia C; Hnida M; Gerhardt E; Lopes da Fonseca T; Villar-Pique A; Branco T; Stahlberg MA; Dean C; Fernández CO; Milosevic I; Outeiro TF Acta Neuropathol Commun; 2018 Aug; 6(1):79. PubMed ID: 30107856 [TBL] [Abstract][Full Text] [Related]
4. Modulation of alpha-synuclein toxicity in yeast using a novel microfluidic-based gradient generator. Fernandes JT; Tenreiro S; Gameiro A; Chu V; Outeiro TF; Conde JP Lab Chip; 2014 Oct; 14(20):3949-57. PubMed ID: 25167219 [TBL] [Abstract][Full Text] [Related]
6. Traffic jams and the complex role of α-Synuclein aggregation in Parkinson disease. Gonçalves SA; Outeiro TF Small GTPases; 2017 Apr; 8(2):78-84. PubMed ID: 27314512 [TBL] [Abstract][Full Text] [Related]
7. Alpha-synuclein blocks ER-Golgi traffic and Rab1 rescues neuron loss in Parkinson's models. Cooper AA; Gitler AD; Cashikar A; Haynes CM; Hill KJ; Bhullar B; Liu K; Xu K; Strathearn KE; Liu F; Cao S; Caldwell KA; Caldwell GA; Marsischky G; Kolodner RD; Labaer J; Rochet JC; Bonini NM; Lindquist S Science; 2006 Jul; 313(5785):324-8. PubMed ID: 16794039 [TBL] [Abstract][Full Text] [Related]
8. Rescuing defective vesicular trafficking protects against alpha-synuclein toxicity in cellular and animal models of Parkinson's disease. Lashuel HA; Hirling H ACS Chem Biol; 2006 Aug; 1(7):420-4. PubMed ID: 17168518 [TBL] [Abstract][Full Text] [Related]
11. Yeast as a drug discovery platform in Huntington's and Parkinson's diseases. Outeiro TF; Giorgini F Biotechnol J; 2006 Mar; 1(3):258-69. PubMed ID: 16897706 [TBL] [Abstract][Full Text] [Related]
12. From Yeast to Humans: Leveraging New Approaches in Yeast to Accelerate Discovery of Therapeutic Targets for Synucleinopathies. Piotrowski JS; Tardiff DF Methods Mol Biol; 2019; 2049():419-444. PubMed ID: 31602625 [TBL] [Abstract][Full Text] [Related]
13. Robust Sequence Determinants of α-Synuclein Toxicity in Yeast Implicate Membrane Binding. Newberry RW; Arhar T; Costello J; Hartoularos GC; Maxwell AM; Naing ZZC; Pittman M; Reddy NR; Schwarz DMC; Wassarman DR; Wu TS; Barrero D; Caggiano C; Catching A; Cavazos TB; Estes LS; Faust B; Fink EA; Goldman MA; Gomez YK; Gordon MG; Gunsalus LM; Hoppe N; Jaime-Garza M; Johnson MC; Jones MG; Kung AF; Lopez KE; Lumpe J; Martyn C; McCarthy EE; Miller-Vedam LE; Navarro EJ; Palar A; Pellegrino J; Saylor W; Stephens CA; Strickland J; Torosyan H; Wankowicz SA; Wong DR; Wong G; Redding S; Chow ED; DeGrado WF; Kampmann M ACS Chem Biol; 2020 Aug; 15(8):2137-2153. PubMed ID: 32786289 [TBL] [Abstract][Full Text] [Related]
14. Trifluoperazine rescues human dopaminergic cells from wild-type α-synuclein-induced toxicity. Höllerhage M; Goebel JN; de Andrade A; Hildebrandt T; Dolga A; Culmsee C; Oertel WH; Hengerer B; Höglinger GU Neurobiol Aging; 2014 Jul; 35(7):1700-11. PubMed ID: 24559643 [TBL] [Abstract][Full Text] [Related]
15. Two low complexity ultra-high throughput methods to identify diverse chemically bioactive molecules using Saccharomyces cerevisiae. Petrovic K; Pfeifer M; Parker CN; Schuierer S; Tallarico J; Hoepfner D; Movva NR; Scheel G; Helliwell SB Microbiol Res; 2017 Jun; 199():10-18. PubMed ID: 28454705 [TBL] [Abstract][Full Text] [Related]
16. Rab1A over-expression prevents Golgi apparatus fragmentation and partially corrects motor deficits in an alpha-synuclein based rat model of Parkinson's disease. Coune PG; Bensadoun JC; Aebischer P; Schneider BL J Parkinsons Dis; 2011; 1(4):373-87. PubMed ID: 23939344 [TBL] [Abstract][Full Text] [Related]
17. FK506 reduces neuroinflammation and dopaminergic neurodegeneration in an α-synuclein-based rat model for Parkinson's disease. Van der Perren A; Macchi F; Toelen J; Carlon MS; Maris M; de Loor H; Kuypers DR; Gijsbers R; Van den Haute C; Debyser Z; Baekelandt V Neurobiol Aging; 2015 Mar; 36(3):1559-68. PubMed ID: 25660193 [TBL] [Abstract][Full Text] [Related]
18. Oxidative and nitrative alpha-synuclein modifications and proteostatic stress: implications for disease mechanisms and interventions in synucleinopathies. Schildknecht S; Gerding HR; Karreman C; Drescher M; Lashuel HA; Outeiro TF; Di Monte DA; Leist M J Neurochem; 2013 May; 125(4):491-511. PubMed ID: 23452040 [TBL] [Abstract][Full Text] [Related]